Skip to main content

Aptevo Therapeutics Inc 8-K, filed Nov 9, 2026

Aptevo Therapeutics Inc. (APVO)

8-K 2026-11-09 For: 2026-11-09
View Original
Added on November 09, 2026

About this 8-K

Aptevo Therapeutics Inc filed this 8-K on November 9, 2026.

Aptevo Therapeutics Inc. reported preclinical results from its November 7, 2026 SITC presentation: APVO451 and APVO452 activated T cells and killed cancer cells under immunosuppressive conditions, while APVO711 combined CD40 activation with PD-L1 blockade. AI summary

Items reported

  • Item 8.01: Other events
  • Item 9.01: Financial statements and exhibits